Circulating biologic markers of endothelial dysfunction in cerebral small vessel disease: A review

Journal of Cerebral Blood Flow and Metabolism

Volumn 36, Issue 1, 2016, Pages 72-94

  Poggesi, Anna ^a   Pasi, Marco ^a   Pescini, Francesca ^b   Pantoni, Leonardo ^a   Inzitari, Domenico ^a,c  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

^c CNR   (Italy)

Author keywords

Cerebral small vessel disease; endothelium; inflammation; lacunar infarcts; white mater hyperintensities

Indexed keywords

BLOOD BRAIN BARRIER; BRAIN ATROPHY; CADASIL; CEREBROVASCULAR DISEASE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; ENDOTHELIUM CELL; FIBRINOLYSIS; HUMAN; HYPERHOMOCYSTEINEMIA; IN VIVO STUDY; INVESTIGATIVE PROCEDURES; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; SELECTIVE ATTENTION; WHITE MATTER; BLOOD; MICROVASCULATURE; PATHOLOGY; PATHOPHYSIOLOGY; VASCULAR ENDOTHELIUM;

BIOLOGICAL MARKER;

BIOMARKERS; BLOOD-BRAIN BARRIER; CEREBRAL SMALL VESSEL DISEASES; ENDOTHELIUM, VASCULAR; HUMANS; MAGNETIC RESONANCE IMAGING; MICROVESSELS;

EID: 84951569612     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1038/jcbfm.2015.116     Document Type: Review

References (92)

1. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 2010; 9: 689-701
2. Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, et al. STandards for ReportIng Vascular changes on nEuroimaging (STRIVE v1). Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 2013; 12: 822-838
3. Poggesi A, Pantoni L, Inzitari D, Fazekas F, Ferro J, et al. The LADIS Study Group. 2001-2011: A Decade of the LADIS (Leukoaraiosis And DISability) Study: what have we learned about white matter changes and small-vessel disease? Cerebrovasc Dis 2011; 32: 577-588
4. Poggesi A, Pantoni L and Inzitari D. Consequences of cerebral small vessel disease: disability, mortality, and prognosis. In: Pantoni L and Gorelick PB (eds) Cerebral small vessel disease. Cambridge University Press: Cambridge, UK, 2014, pp.273-382
5. Debette S and Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ 2010; 26: c3666
6. Wardlaw JM, Smith C and Dichgans M. Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging. Lancet Neurol 2013; 12: 483-497
7. Deanfield JE, Halcox JP and Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation 2007; 115: 1285-1295
8. Pries AR, Secomb TW and Gaehtgens P. The endothelial surface layer. Pflugers Arch 2000; 440: 653-666
9. Michiels C. Endothelial cell functions. J Cell Physiol 2003; 196: 430-443
10. Pearson JD. Endothelial cell function and thrombosis. Baillieres Best Pract Res Clin Haematol 1999; 12: 329-341
11. Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998; 91: 3527-3561
12. Murphey HS. Inflammation. In: Streyer Rubin (ed.) Rubin's pathology: Clinicopathologic foundations of medicine. Lippincott Williams and Wilkins: Philadelphia, PA, 2012, pp.23-44
13. Nathan C. Points of control in inflammation. Nature 2002; 420: 846-852
14. Pescini F and Abbate R. Markers of endothelial dysfunction, oxidative stress, and inflammation in cerebral small vessel disease. In: Gorelick Pantoni (ed.) Cerebral small vessel disease. Cambridge University Press: Cambridge, UK, 2014, pp.192-199
15. Burger D and Touyz RM. Cellular biomarkers of endothelial health: microparticles, endothelial progenitor cells, and circulating endothelial cells. J Am Soc Hypertens 2012; 6: 85-99
16. Beck H, Voswinckel R, Wagner S, Ziegelhoeffer T, Heil M, Helisch A, et al. Participation of bone marrowderived cells in long-term repair processes after experimental stroke. J Cereb Blood Flow Metab 2003; 23: 709-717
17. Cheng Z, Yang X and Wang H. Hyperhomocysteinemia and endothelial dysfunction. Curr Hypertens Rev 2009; 5: 158-165
18. Szmitko PE, Wang CH, Weisel RD, de Almeida JR, Anderson TJ and Verma S. New markers of inflammation and endothelial cell activation: Part I. Circulation 2003; 108: 1917-1923
19. Franceschelli S, Ferrone A, Pesce M, Riccioni G and Speranza L. Biological functional relevance of asymmetric dimethylarginine (ADMA) in cardiovascular disease. Int J Mol Sci 2013; 14: 24412-24421
20. Neuwelt EA, Bauer B, Fahlke C, Fricker G, Iadecola C, Janigro D, et al. Engaging neuroscience to advance translational research in brain barrier biology. Nat Rev Neurosci 2011; 12: 169-182
21. del Zoppo GJ. Aging and the neurovascular unit. Ann NY Acad Sci 2012; 1268: 127-133
22. Iadecola C. The pathobiology of vascular dementia. Neuron 2013; 80: 844-866
23. Abbott NJ, Rönnbäck L and Hansson E. Astrocyteendothelial interactions at the blood-brain barrier. Nat Rev Neurosci 2006; 7: 41-53
24. Markus HS, Allan CL and Ebmeier KP. Cerebral hemodynamics in cerebral small vessel disease. In: Pantoni L and Gorelick PB (eds) Cerebral small vessel disease. Cambridge University Press: Cambridge, UK, 2014, pp.180-191
25. Markus HS, Lythgoe DJ, Ostegaard L, O'Sullivan Mand Williams SC. Reduced cerebral blood flow in white matter in ischaemic leukoaraiosis demonstrated using quantitative exogenous contrast based perfusion MRI. J Neurol Neurosurg Psychiatry 2000; 69: 48-53
26. O'Sullivan M, Lythgoe DJ, Pereira AC, Summers PE, Jarosz JM, Williams SC and Markus HS. Patterns of cerebral blood flow reduction in patients with ischemic leukoaraiosis. Neurology 2002; 59: 321-326
27. Gunarathne A, Patel JV, Kausar S, Gammon B, Hughes EA and Lip GY. Glycemic status underlies increased arterial stiffness and impaired endothelial function in migrant South Asian stroke survivors compared to European Caucasians pathophysiological insights from the West Birmingham Stroke Project. Stroke 2009; 40: 2298-2306
28. Deplanque D, Lavallee PC, Labreuche J, Gongora-Rivera F, Jaramillo A, Brenner D, et al. Lacunar-BICHAT Investigators. Cerebral and extracerebral vasoreactivity in symptomatic lacunar stroke patients: a case-control study. Int J Stroke 2013; 8: 413-421
29. Thompson CS and Hakim AM. Living beyond our physiological means: small vessel disease of the brain is an expression of a systemic failure in arteriolar function: a unifying hypothesis. Stroke 2009; 40: e322-e330
30. Wada M, Nagasawa H, Iseki C, Takahashi Y, Sato H, Arawaka S, et al. Cerebral small vessel disease and chronic kidney disease (CKD): results of a cross-sectional study in community-based Japanese elderly. J Neurol Sci 2008; 272: 36-42
31. Wada M, Nagasawa H, Kurita K, Koyama S, Arawaka S, Kawanami T, et al. Microalbuminuria is a risk factor for cerebral small vessel disease in community-based elderly subjects. J Neurol Sci 2007; 255: 27-34
32. Ruchoux MM, Brulin P, Leteurtre E and Maurage CA. Skin biopsy value and leukoaraiosis. Ann NY Acad Sci 2000; 903: 285-292
33. Martens RJ, Vink H, van Oostenbrugge RJ and Staals J. Sublingual microvascular glycocalyx dimensions in lacunar stroke patients. Cerebrovasc Dis 2013; 35: 451-454
34. Pretnar-Oblak J, Sabovic M, Pogacnik T, Sebestjen M and Zaletel M. Flow-mediated dilatation and intimamedia thickness in patients with lacunar infarctions. Acta Neurol Scand 2006; 113: 273-277
35. Wharton SB, Simpson JE, Brayne C and Ince PG. Ageassociated white matter lesions: the MRC Cognitive Function and Ageing Study. Brain Pathol 2015; 25: 35-43
36. Young VG, Halliday GM and Kril JJ. Neuropathologic correlates of white matter hyperintensities. Neurology 2008; 71: 804-811
37. Fernando MS, Simpson JE, Matthews F, Brayne C, Lewis CE, Barber R, et al. White matter lesions in an unselected cohort of the elderly: molecular pathology suggests origin from chronic hypoperfusion injury. Stroke 2006; 37: 1391-1398
38. Simpson JE, Fernando MS, Clark L, Ince PG, Matthews F, Forster G, et al. White matter lesions in an unselected cohort of the elderly: astrocytic, microglial and oligodendrocyte precursor cell responses. Neuropathol Appl Neurobiol 2007; 33: 410-419
39. Simpson JE, Ince PG, Higham CE, Gelsthorpe CH, Fernando MS, Matthews F, et al. MRC Cognitive Function and Ageing Neuropathology Study Group. Microglial activation in white matter lesions and nonlesional white matter of ageing brains. Neuropathol Appl Neurobiol 2007; 33: 670-683
40. Al-Mashhadi S, Simpson JE, Heath PR, Dickman M, Forster G, Matthews FE, et al. Medical Research Council Cognitive Function and Ageing Study. Oxidative glial cell damage associated with white matter lesions in the aging human brain. Brain Pathol, advance online publication, 14 October 2014; doi:10.1111/ bpa.12216
41. Wardlaw JM, Sandercock PA, Dennis MS and Starr J. Is breakdown of the blood-brain barrier responsible for lacunar stroke, leukoaraiosis, and dementia? Stroke 2003; 34: 806-812
42. Wallin A, Blennow K, Fredman P, Gottfries CG, Karlsson I and Svennerholm L. Blood brain barrier function in vascular dementia. Acta Neurol Scand 1990; 81: 318-322
43. Skoog I, Wallin A, Fredman P, Hesse C, Aevarsson O, Karlsson I, et al. A population study on blood-brain barrier function in 85-year-olds: relation to Alzheimer's disease and vascular dementia. Neurology 1998; 50: 966-971
44. Pantoni L, Inzitari D, Pracucci G, Lolli F, Giordano G, Bracco L and Amaducci L. Cerebrospinal fluid proteins in patients with leucoaraiosis: possible abnormalities in blood-brain barrier function. J Neurol Sci 1993; 115: 125-1231
45. Wardlaw JM, Farrall A, Armitage PA, Carpenter T, Chappell F, Doubal F, et al. Changes in background blood-brain barrier integrity between lacunar and cortical ischemic stroke subtypes. Stroke 2008; 39: 1327-1332
46. Topakian R, Barrick TR, Howe FA and Markus HS. Blood-brain barrier permeability is increased in normalappearing white matter in patients with lacunar stroke and leucoaraiosis. J Neurol Neurosurg Psychiatry 2010; 81: 192-197
47. Wardlaw JM and Pantoni L. Sporadic small vessel disease: pathogenic aspects. In: Pantoni L and Gorelick PB (eds) Cerebral small vessel disease. Cambridge University Press: Cambridge, UK, 2014, pp.52-63
48. Aono Y, Ohkubo T, Kikuya M, Hara A, Kondo T, Obara T, et al. Plasma fibrinogen, ambulatory blood pressure, and silent cerebrovascular lesions: the Ohasama study. Arterioscler Thromb Vasc Biol 2007; 27: 963-968
49. Aribisala BS, Wiseman S, Morris Z, Valdés-Hernández MC, Royle NA, Maniega SM, et al. Circulating inflammatory markers are associated with magnetic resonance imaging-visible perivascular spaces but not directly with white matter hyperintensities. Stroke 2014; 45: 605-607
50. Dufouil C, Alpérovitch A, Ducros V and Tzourio C. Homocysteine white matter hyperintensities, and cognition in healthy elderly people. Ann Neurol 2003; 53: 214-221
51. Fornage M, Chiang YA, O'Meara ES, Psaty BM, Reiner AP, Siscovick DS, et al. Biomarkers of inflammation and MRI-defined small vessel disease of the brain: the Cardiovascular Health Study. Stroke 2008; 39: 1952-1959
52. Gottesman RF, Cummiskey C, Chambless L, Wu KK, Aleksic N, Folsom AR, et al. Hemostatic factors and subclinical brain infarction in a community-based sample: the ARIC study. Cerebrovasc Dis 2009; 28: 589-594
53. Kloppenborg RP, Nederkoorn PJ, van der Graaf Y and Geerlings MI. Homocysteine and cerebral small vessel disease in patients with symptomatic atherosclerotic disease. The SMART-MR study. Atherosclerosis 2011; 216: 461-466
54. Notsu Y, Nabika T, Bokura H, Suyama Y, Kobayashi S, Yamaguchi S, et al. Evaluation of asymmetric dimethyalarginine and homocysteine in microangiopathy-related cerebral damage. Am J Hypertens 2009; 22: 257-262
55. Pikula A, Böger RH, Beiser AS, Maas R, DeCarli C, Schwedhelm E, et al. Association of plasma ADMA levels with MRI markers of vascular brain injury: Framingham offspring study. Stroke 2009; 40: 2959-2964
56. Pikula A, Beiser AS, DeCarli C, Himali JJ, Debette S, Au R, et al. Multiple biomarkers and risk of clinical and subclinical vascular brain injury: the Framingham Offspring Study. Circulation 2012; 125: 2100-2107
57. Pikula A, Beiser AS, Chen TC, Preis SR, Vorgias D, DeCarli C, et al. Serum brain-derived neurotrophic factor and vascular endothelial growth factor levels are associated with risk of stroke and vascular brain injury: Framingham Study. Stroke 2013; 44: 2768-2775
58. Romero JR, Preis SR, Beiser AS, DeCarli C, Lee DY, Viswanathan A, et al. Lipoprotein phospholipase A2 and cerebral microbleeds in the Framingham Heart Study. Stroke 2012; 43: 3091-3094
59. Sachdev P, Parslow R, Salonikas C, Lux O, Wen W, Kumar R, et al. Homocysteine and the brain in midadult life: evidence for an increased risk of leukoaraiosis in men. Arch Neurol 2004; 61: 1369-1376
60. Satizabal CL, Zhu YC, Mazoyer B, Dufouil C and Tzourio C. Circulating IL-6 and CRP are associated with MRI findings in the elderly: the 3C-Dijon Study. Neurology 2012; 78: 720-727
61. van Dijk EJ, Prins ND, Vermeer SE, Vrooman HA, Hofman A, Koudstaal PJ, et al. C-reactive protein and cerebral small-vessel disease: the Rotterdam Scan Study. Circulation 2005; 112: 900-905
62. Vermeer SE, van Dijk EJ, Koudstaal PJ, Oudkerk M, Hofman A, Clarke R, et al. Homocysteine, silent brain infarcts, and white matter lesions: the Rotterdam Scan Study. Ann Neurol 2002; 51: 285-289
63. Wada M, Nagasawa H, Kurita K, Koyama S, Arawaka S, Kawanami T, et al. Cerebral small vessel disease and C-reactive protein: results of a cross-sectional study in community-based Japanese elderly. J Neurol Sci 2008; 15: 43-49
64. Wersching H, Duning T, Lohmann H, Mohammadi S, Stehling C, Fobker M, et al. Serum C-reactive protein is linked to cerebral microstructural integrity and cognitive function. Neurology 2010; 30: 1022-1029
65. Wright CB, Paik MC, Brown TR, Stabler SP, Allen RH, Sacco RL, et al. Total homocysteine is associated with white matter hyperintensity volume: the Northern Manhattan Study. Stroke 2005; 36: 1207-1211
66. Wright CB, Moon Y, Paik MC, Brown TR, Rabbani L, Yoshita M, et al. Inflammatory biomarkers of vascular risk as correlates of leukoariosis. Stroke 2009; 40: 3466-3471
67. Yoshida M, Tomitori H, Machi Y, Katagiri D, Ueda S, Horiguchi K, et al. Acrolein, IL-6 and CRP as markers of silent brain infarction. Atherosclerosis 2009; 203: 557-562
68. Han JH, Wong KS, Wang YY, Fu JH, Ding D and Hong Z. Plasma level of sICAM-1 is associated with the extent of white matter lesion among asymptomatic elderly subjects. Clin Neurol Neurosurg 2009; 111: 847-851
69. Hoshi T, Kitagawa K, Yamagami H, Furukado S, Hougaku H and Hori M. Relations of serum highsensitivity C-reactive protein and interleukin-6 levels with silent brain infarction. Stroke 2005; 36: 768-772
70. Kim Y, Kim YK, Kim NK, Kim SH, Kim OJ and Oh SH. Circulating matrix metalloproteinase-9 level is associated with cerebral white matter hyperintensities in nonstroke individuals. Eur Neurol 2014; 72: 234-240
71. Miralbell J, Soriano JJ, Spulber G, López-Cancio E, Arenillas JF, BargallóN, et al. Structural brain changes and cognition in relation to markers of vascular dysfunction. Neurobiol Aging 2012; 33: e9-17
72. Miwa K, Tanaka M, Okazaki S, Furukado S, Sakaguchi M and Kitagawa K. Relations of blood inflammatory marker levels with cerebral microbleeds. Stroke 2011; 42: 3202-3206
73. Tomimoto H, Akiguchi I, Ohtani R, Yagi H, Kanda M, Shibasaki H and Yamamoto Y. The coagulationfibrinolysis system in patients with leukoaraiosis and Binswanger disease. Arch Neurol 2001; 58: 1620-1625
74. Kario K, Matsuo T, Kobayashi H, Hoshide S and Shimada K. Hyperinsulinemia and hemostatic abnormalities are associated with silent lacunar cerebral infarcts in elderly hypertensive subjects. J Am Coll Cardiol 2001; 37: 871-877
75. Rouhl RP, Mertens AE, van Oostenbrugge RJ, Damoiseaux JG, Debrus-Palmans LL, Henskens LH, et al. Angiogenic T-cells and putative endothelial progenitor cells in hypertension-related cerebral small vessel disease. Stroke 2012; 43: 256-258
76. Hassan A, Hunt BJ, O'Sullivan M, Parmar K, Bamford JM, Briley D, Brown MM, et al. Markers of endothelial dysfunction in lacunar infarction and ischaemic leukoaraiosis. Brain 2003; 126: 424-432
77. Hassan A, Hunt BJ, O'Sullivan M, Bell R, D'Souza R, Jeffery S, et al. Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction. Brain 2004; 127: 212-219
78. Khan U, Hassan A, Vallance P and Markus HS. Asymmetric dimethylarginine in cerebral small vessel disease. Stroke 2007; 38: 411-413
79. Knottnerus IL, Govers-Riemslag JW, Hamulyak K, Rouhl RP, Staals J, Spronk HM, et al. Endothelial activation in lacunar stroke subtypes. Stroke 2010; 78: 493-498
80. Knottnerus IL, Winckers K, Ten Cate H, Hackeng TM, Lodder J, Rouhl RP, et al. Levels of heparin-releasable TFPI are increased in first-ever lacunar stroke patients. Neurology 2012; 78: 493-498
81. Naka H, Nomura E, Takahashi T, Wakabayashi S, Kajikawa H, Kohriyama T, et al. Plasma total homocysteine levels are associated with advanced leukoaraiosis but not with asymptomatic microbleeds on T2-weighted MRI in patients with stroke. Eur J Neurol 2006; 13: 261-265
82. Rouhl RP, van Oostenbrugge RJ, Damoiseaux JG, Debrus-Palmans LL, Theunissen RO, Knottnerus IL, et al. Haptoglobin phenotype may alter endothelial progenitor cell cluster formation in cerebral small vessel disease. Curr Neurovasc Res 2009; 6: 32-41
83. Rouhl RP, van Oostenbrugge RJ, Theunissen RO, Knottnerus IL, Staals J, Henskens LH, et al. Autoantibodies against oxidized low-density lipoprotein in cerebral small vessel disease. Stroke 2010; 41: 2687-2689
84. Rouhl RP, Damoiseaux JG, Lodder J, Theunissen RO, Knottnerus IL, Staals J, et al. Vascular inflammation in cerebral small vessel disease. Neurobiol Aging 2012; 33: 1800-1806
85. Markus HS, Hunt B, Palmer K, Enzinger C, Schmidt H and Schmidt R. Markers of endothelial and hemostatic activation and progression of cerebral white matter hyperintensities: longitudinal results of the Austrian Stroke Prevention Study. Stroke 2005; 36: 1410-1414
86. Rufa A, Blardi P, De Lalla A, Cevenini G, De Stefano N, Zicari E, et al. Plasma levels of asymmetric dimethylarginine in cerebral autosomal dominant arteriopathy with subcortical infarct and leukoencephalopathy. Cerebrovasc Dis 2008; 26: 636-640
87. Flemming KD, Nguyen TT, Abu-Lebdeh HS, Parisi JE, Wiebers DO, Sicks JD, et al. Hyperhomocysteinemia in patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). Mayo Clin Proc 2001; 76: 1213-1218
88. Singhal S, Bevan S, Barrick T, Rich P and Markus HS. The influence of genetic and cardiovascular risk factors on the CADASIL phenotype. Brain 2004; 127: 2031-2038
89. Campolo J, De Maria R, Frontali M, Taroni F, Inzitari D, Federico A, et al. Impaired vasoreactivity in mildly disabled CADASIL patients. J Neurol Neurosurg Psychiatry 2012; 83: 268-274
90. Pescini F, Cesari F, Giusti B, Sarti C, Zicari e, Bianchi S, et al. Bone marrow-derived progenitor cells in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Stroke 2010; 41: 218-223
91. Del Bene A, Makin SD, Doubal FN, Inzitari D and Wardlaw JM. Variation in risk factors for recent small subcortical infarcts with infarct size, shape, and location. Stroke 2013; 44: 3000-3006
92. Markus HS. Genes, endothelial function and cerebral small vessel disease in man. Exp Physiol 2008; 93: 121-127.